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C H A P T E R  7 
The Etiology and Treatment 
of Nicotine Dependence 
A Biopsychosocial Perspective 
hronic use of tobacco-containing 
products, particularly cigarettes, 
remains one of the most avoidable 
causes of death and illness in the United States 
and claims the lives of more than 430,000 indi- 
viduals each year (U.S. Department of Health 
and Human Services [DHHS], 1999). The 
number of tobacco-related deaths alone 
exceeds that of deaths due to AIDS, murders, 
other drugs, alcohol, car crashes, fires, and sui- 
cides combined (Centers for Disease Control 
and Prevention [CDC], 2002). Illnesses associ- 
ated with tobacco use include, but are not 
limited to, laryngeal cancer, oral cancer, 
esophageal cancer, obstructive pulmonary dis- 
ease, cardiovascular disease, intrauterine 
growth retardation, and low birth weight 
(DHHS, 1999). Evidence of significant health 
risks due to environmental tobacco smoke has 
also been documented. Adverse health risks 
caused by exposure to "secondhand" tobacco 
smoke include lung cancer, asthma, respiratory 
infections, and decreased pulmonary function 
(DHHS, 1999). Despite public health efforts to 
reduce tobacco use in the United States, adult 
prevalence rates have not changed signifi- 
cantly, and in some cases increases were 
observed during the 1990s (CDC, 2002). For 
example, the overall rate of adult cigarette 
smokers has decreased slightly from 25.0% to 
23.3% across all age groups except that of 18- 
to 24-year-olds (CDC, 2002), whereas the use 
of smokeless (spit) tobacco and cigars has 
increased substantially (U.S. Department of 
Agriculture, 1997). To date, 65.5 million 
Americans continue to use tobacco products 
on a regular basis (CDC, 2002) and appear to 
be more difficult to treat than their counter- 
parts of the 1970s and 1980s (Irvin & 
Brandon, 2000). As such, tobacco use contin- 
ues to represent an important health behavior 
that faces health care professionals. 
102 BEHAVIORS THAT COMPROMISE HEALTH 
DEFINITIONS AND DESCRIPTION 
OF NICOTINE DEPENDENCE 
The addictive process associated with tobacco 
use has been studied primarily with cigarette 
smoking, but there is a growing body of litera- 
ture examining this process in spit tobacco (e.g., 
Hatsukami & Severson, 1999; McChargue & 
Collins, 1998) and cigar use (e.g., Henningfield, 
Fant, Radzius, & Frost, 1999). The DSM-IV- 
TR (Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition, text revision 
[American Psychiatric Association, 20001) 
classifies chronic tobacco use as a significant 
clinical impairment because of the psycho- 
logical and neurobiological effects caused by 
nicotine-the presumed addictive ingredient 
found in tobacco products (Henningfield & 
Heishman, 1995; Robinson & Pritchard, 
1992). As a clinical disorder, chronic tobacco 
use is classified as nicotine dependence when 
three of seven criteria are met within the same 
12-month period. In particular, the four most 
prominent criteria of nicotine dependence are 
(a) developing a tolerance to nicotine, (b) expe- 
riencing nicotine withdrawal, (c) showing a 
persistent desire or unsuccessful efforts to quit 
or cut down the use of nicotine, and (d) contin- 
uing to use nicotine despite the development of 
physical or psychological problems that are 
likely to have been caused or exacerbated by 
tobacco products (American Psychiatric 
Association, 2000). Other general criteria for 
nicotine dependence include using larger 
amounts over a longer period of time; spending 
a great deal of time in activities necessary to 
obtain, use, or recover from nicotine; and expe- 
riencing impaired functioning (American 
Psychiatric Association, 2000). 
Tolerance 
Simply stated, tolerance is viewed as a 
diminished response or an adaptation to a 
given dose after repeated use (Balfour, 1991; 
Benowitz, 1990). Subjective, behavioral, and 
physiological adaptation has been shown 
following repeated exposure to nicotine 
(Balfour, 1991). For example, dizziness, nau- 
sea, and vomiting are associated with initial 
exposure to cigarette smoking; however, 
these symptoms disappear rapidly following 
habitual exposure (Benowitz, 1990). For the 
most part, tolerance to nicotine develops 
quickly, sometimes within 35 minutes of 
administration (Porchet, Benowitz, & Sheiner, 
198 8). Once tolerance is developed, certain 
effects (e.g., dizziness) are more transient and 
dissipate rapidly following a short period of 
abstinence (Benowitz, 1990), whereas toler- 
ance to most of the subjective and behavioral 
effects appears to be more long term (Perkins 
et al., 2001). Researchers have suggested that 
the rapid "re-sensitization" of the more tran- 
sient effects, such as the "rush" one experi- 
ences from the first cigarette of the day, may 
partially explain why tobacco users tend to 
show stable use patterns without progressively 
increasing their dose amounts over time 
(Benowitz, 1990). 
Nicotine Withdrawal 
Nicotine withdrawal is defined as the mani- 
festation of behavioral, subjective, physiologi- 
cal, and biochemical changes that occur when 
a person abruptly cuts down or quits using 
nicotine-containing products (Hughes, Higgins, 
& Hatsukami, 1990). The withdrawal syn- 
drome includes four or more of the following 
symptoms: (a) dysphoric or depressed mood; 
(b) insomnia; (c) irritability, frustration, or 
anger; (d) anxiety; (e) difficulty in concentrat- 
ing; (f) restlessness; (g) decreased heart rate; 
and (h) increased appetite or weight gain 
(American Psychiatric Association, 2000). In 
addition, these symptoms cause clinically sig- 
nificant distress or impairment in social, occu- 
pational, or other important areas of 
functioning, and the symptoms are not better 
accounted for by another mental disorder 
(American Psychiatric Association, 2000). 
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Declining blood levels of nicotine have been 
associated with the onset of nicotine with- 
drawal; however, it is not clear whether the 
duration and severity of these symptoms are 
entirely attributable to the rate at which nico- 
tine dissipates from a person's system. For 
example, nicotine reaches the brain within 10 
to 19 seconds after smoking a cigarette, with 
brain levels of nicotine declining rapidly over 
20 to 30 minutes (Benowitz, 1990). On the 
other hand, nicotine levels in the brain from spit 
tobacco tend to increase gradually, reaching 
their peak about 30 minutes after administra- 
tion, and decline slowly over 2 hours or more 
(Benowitz, Porchet, & Jacob, 1990). Despite 
the differing rates of nicotine absorption and 
depletion observed across these two modes of 
administration, spit tobacco users consistently 
report similar experiences of withdrawal, 
both in terms of the types of symptoms expe- 
rienced (Hatsukami, Gust, & Keenan, 1987; 
McChargue & Collins, 1998; McChargue, 
Collins, & Cohen, 2002) and in terms of the 
level of severity (McChargue & Collins, 1998). 
Thus, the severity of withdrawal symptoms 
may be dictated by a variety of individual dif- 
ferences, including tobacco use patterns (Killen, 
Fortmann, Newman, & Varady, 1991), psy- 
chiatric comorbidities (Pomerleau, Marks, & 
Pomerleau, 2000), and personality factors 
(Gilbert & Gilbert, 1995; Madden et al., 1997). 
In general, nicotine withdrawal occurs within 
24 hours of abruptly reducing or quitting nico- 
tine use, peaks between 48 hours (Hughes & 
Hatsukami, 1986) and 2 weeks (Shlffman, Paty, 
Guys, Kassel, & Elash, 1995; West, Hajek, & 
Belcher, 1989), and resolves after 1 month of 
abstinence (Hughes, 1992). However, similar 
to withdrawal severity, the duration of with- 
drawal patterns are also variable. For example, 
increases in hunger and weight gain are the most 
persistent symptoms, lasting as long as 6 months 
to 1 year (Hughes, 1992; Klesges et al., 1997). 
In addition, individuals who quit using nicotine- 
containing products do not always report 
increased anxiety; however, in cases where , 
anxiety is reported, it could be a function of 
brief lapses in their abstinence (e.g., periodically 
smoking one cigarette and then resuming absti- 
nence west  & Hajek, 1997). Finally, depres- 
sive symptoms may persist beyond 1 month, 
especially among people who have experienced 
a major depressive episode in the past (Borrelli 
et al., 1996). In fact, data suggest that there is at 
least a 33% chance that people with a hstory of 
major depression will experience clinically sig- 
lllficant levels of depressive symptoms at any 
time across the first 12 months of nicotine absti- 
nence (Borrelli et al., 1996; Tsoh et al., 2000). 
Other Prominent Criteria 
for Nicotine Dependence 
Individuals who use nicotine-containing 
products also show signs and symptoms associ- 
ated with the remaining criteria for nicotine 
dependence. Specifically, a strong and persis- 
tent desire to use tobacco maintains use 
patterns (Baker, Morse, & Sherman, 1986; 
Tiffany, 1990) and contributes to difficulties in 
quitting (e.g., Tracy, 1994). Researchers ques- 
tion whether nicotine's ability to alter emo- 
tions (Baker et al., 1986; Carmody, 1990; Hall, 
Munoz, Reus, & Sees, 1993) drives the motiva- 
tion to use tobacco products or whether this 
increased motivation is more automatic 
(Tiffany, 1990) and independent from emotion 
(Robinson & Berridge, 2000). Nevertheless, 
nicotine administration appears to create an 
intense motivation to use tobacco products that 
is difficult to break regardless of the mechanism 
that promotes the powerful desire to continue 
tobacco use. 
Individuals who use tobacco also tend to 
experience extreme difficulty in quitting, and 
unsuccessful efforts usually are made before 
they are able to quit permanently. In fact, less 
than 5% of individuals who meet criteria 
for nicotine dependence are able to quit on 
their own (Fiore et al., 1990). This percentage 
increases to as high as 30% with assisted 
treatment for nicotine dependence (Fiore et al., 
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2000). As stated earlier, fewer and fewer 
people have quit using tobacco products over 
the past decade (CDC, 2002) as compared 
with previous decades (Emrnons, Kawachi, & 
Barclay, 1997). The apparent plateau of 
cigarette smoking rates and the increase of spit 
tobacco and cigar use may suggest that today's 
tobacco users are more resistant to treatment 
efforts and may even possess underlying vul- 
nerabilities that further establish tobacco use 
patterns (Gilbert & Gilbert, 1995). 
Finally, it is not uncommon for nicotine- 
dependent individuals to continue to use 
tobacco products despite physical or psycho- 
logical problems that may result from chronic 
nicotine exposure. Familiar examples include 
the patient with emphysema who continues 
to smoke while attached to an oxygen tank 
despite the inherent danger of doing so and 
the patient who smokes through a tra- 
cheotomy tube. Overall, there is anecdotal 
and empirical evidence suggesting that many 
patients with cardiovascular disease, chronic 
obstructive pulmonary disease, and/or cancer- 
all of which are related to chronic tobacco use 
(DHHS, 1999)--continue their patterns of 
use (Gritz, Kristeller, & Burns, 1993). 
Moreover, continued use is associated with a 
heightened mortality rate, whereas cessation 
post-disease diagnosis may improve prog- 
noses (Gritz et al., 1993). 
A BIOPSYCHOSOCIAL 
LEARNING MODEL OF 
NICOTINE DEPENDENCE 
Nicotine dependence is a complex biopsy- 
chosocial phenomenon that originates from 
learning theory. The most parsimonious expla- 
nation is that nicotine's effects on neurobio- 
logical substrates interact with behavioral, 
emotional, and cognitive domains to create 
dependence. Evidence also suggests that 
chronic use patterns may produce secondary 
conditioning of the pharmacological effects on 
the brain (Rose & Levin, 1991) and sensitization 
of some neurobiological systems (Robinson & 
Berridge, 2000; Watkins, Koob, & Markou, 
2000). In general, tobacco use behaviors are 
maintained by nicotine's ability to enhance 
desirable effects (positive reinforcement) and to 
dispel undesirable effects (negative reinforce- 
ment). Over time, frequent and repeated use of 
tobacco products in specific situations, environ- 
ments, and emotional states may automatically 
trigger tobacco use (secondary conditioning 
and sensitization) (Rose & Levin, 1991; 
Shiffrnan, 1991). For example, a person who 
typically smokes while talking on the phone 
may light another cigarette when the phone 
rings without realizing that he or she already 
had a cigarette lit. 
Positive Reinforcement 
and Sensitization: A Sto y 
of Rewarding Properties 
The most widely studied neurobiological 
substrate associated with nicotine-related 
positive reinforcement is dopamine (Wise, 
1998). The mesolimbic dopamine system has 
long been touted as the reward center of the 
brain that shapes goal-directed behavior 
(Olds & Milner, 1954; Stein, Belluzzi, 
Ritter, & Wise, 1974), including drug use 
behavior (Di Chiara, 1998; Koob & Le 
Moal, 1997). Consistent with the reward 
hypothesis of dopamine, nicotine's preferen- 
tial binding to nicotinic cholinergic receptors 
within the mesolimbic dopamine system 
(Clarke & Pert, 1985) and nicotine's reliable 
activation of dopamine release within the 
same system (Pomerleau & Pomerleau, 1984) 
suggest that nicotine produces powerful 
rewarding effects for people who use tobacco. 
The rewarding effects of nicotine become 
more powerful over time due to the biphasic 
nature of nicotine's influence on dopamine 
release. During nicotine administration, the 
dopaminergic system becomes sensitized 
rather than habituated (e.g., tolerance) 
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(Robinson & Berridge, 2000; Watkins et al., 
2000). In other words, dopamine release is 
enhanced, rather than diminished, from 
repeated exposure to nicotine. As levels of 
nicotine are depleted during abstinence, 
dopamine also shows neuroadaptative effects. 
Neuroadaptation reflects the progressive 
blunting of naturally occurring dopamine 
(Epping-Jordan, Watkins, Koob, & Markou, 
1998). The ever-growing disparity between 
sensitized dopamine release from nicotine 
administration and blunted naturally occur- 
ring dopamine release during nicotine absti- 
nence is hypothesized to alter reward 
thresholds (Watkins et al., 2000), presumably 
making it very difficult for tobacco users 
to experience pleasure without the aid of 
nicotine. 
Glutamate functioning also appears to play 
an important role in the positive reinforcement 
of nicotine via its symbiotic relationship with 
dopamine. As discussed earlier, dopaminergic 
functioning is regarded as the primary mecha- 
nism that accounts for the rewarding properties 
of nicotine. However, glutamate may actually 
strengthen nicotine's rewarding properties and 
permanently implant the effect of such reward 
into long-term memory. For instance, nicotine 
administration has been shown to increase glu- 
tamate release within the mesolimbic dopamine 
system (Garcia-Munoz, Patino, Young, & 
Groves, 1996) as well as within hippocampal 
neurons associated with memory and learning 
(Radcliffe, Fisher, Gray, & Dani, 1999). Given 
that glutamate is strongly linked to learning and 
memory (Goda & Stevens, 1996), it has been 
hypothesized that the simultaneous activation 
of the hippocampal and dopaminergic systems 
solidifies the rewarding properties of nicotine 
(Mansvelder & McGehee, 2000). Even after 
long periods of abstinence, the responsiveness 
of these systems to nicotine remains abnormal, 
suggesting that these neurotransmitters play a 
substantial role in the long-lasting, enduring 
changes associated with nicotine dependence 
(Pulvirenti & Diana, 2001). 
These long-lasting memories may help to 
explain the incongruent psychosocial findmgs 
related to the reward obtained from nicotine 
administration. A standard assumption has 
been that self-reported pleasure (e.g., positive 
affect or euphoria) acts as a substitute for the 
rewarding effects of nicotine. However, empiri- 
cal evidence has not consistently produced data 
to support ths assumption. If self-reported plea- 
sure mimicked the neurobiological substrates, 
one would expect that pleasure would show 
sensitizing effects (i.e., more and more pleasure 
from repeated exposure) after nicotine adrmnis- 
tration and would show acute decreases in 
pleasure during nicotine abstinence. Although 
research shows the expected decrease in plea- 
sure following nicotine abstinence (Hughes & 
Hatsukami, 1986), euphoric effects during nico- 
tine administration are minimal (Pomerleau & 
Pomerleau, 1992) and may further dmmish, 
rather than increase, with repeated exposure 
(Robinson & Berridge, 2000). If pleasure dimin- 
ishes with chronic nicotine use and is not llnked 
with doparnine sensitization, memories about 
the pleasure-enhancing effects of nicotine may 
be sufficient for continued motivation to self- 
a b s t e r  nicotine. 
As noted earlier, the rewarding effects of 
nicotine are long-lasting in a tobacco user's 
memory system. A plausible psychosocial 
mechanism that takes into account these 
embedded reward effects is positive smoking 
expectancies or the belief that smoking will 
lead to a positive outcome (e.g., relaxation). 
For decades, positive drug expectancies have 
been shown to reflect long-term drug use pat- 
terns (Vuchinich & Tucker, 1988). In fact, a 
recent study showed that smoking outcome 
expectancies combine with one's tendency 
to experience negative affective states to 
predict smoking behavior over time (Cohen, 
McCarthy, Brown, & Myers, 2002). These 
findings indicate that at least part of the 
commonly observed relationship between 
negative affect and smoking behavior can be 
explained by smoking expectancies. 
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Negative Reinforcement: 
A Story of Emotion Regulation 
When considering negative reinforcement 
associated with tobacco use disorders, nicotine 
administration is believed to have negative 
mood-alleviating properties via its manipula- 
tion of neurotransmitters such as serotonin 
  car mod^, 1990; Hall et al., 1993). Specifi- 
cally, low levels of serotonin have been strongly 
associated with negative mood states (Maes & 
Meltzer, 1995), and nicotine administration 
appears to increase levels of this neurotrans- 
mitter (Kenny, File, & Neal, 2000). In fact, 
nicotine's ability to elevate serotonin levels 
may partially explain why people report that 
using nicotine-containing products alleviates 
negative affective states   car mod^, 1990; Hall 
et al., 1993). Consistent with the serotonin 
hypothesis of nicotine dependence, when one 
abstains from nicotine, medications that 
improve the efficiency of serotonin (e.g., sero- 
tonin reuptake inh~bitors such as fluoxetine) 
prolong short-term abstinence (Niaura et al., 
2002), particularly among smokers with high 
baseline levels of depression (Hitsman et al., 
1999). Moreover, once people abstaining from 
nicotine are taken off of this type of medication, 
there is an increased likelihood that they will 
experience a major depressive episode (e.g., 
Borrelli et al., 1996). Hence, this depressive vul- 
nerability during nicotine abstinence is particu- 
larly salient for depression-prone individuals. 
Although many people report using tobacco 
products due to their negative mood-alleviating 
properties (Spielberger, Foreyt, Reheiser, & 
Poston, 1998), psychosocial research investigat- 
ing this hypothesis is mixed. It is clear that after 
short-term abstinence, nicotine administration 
will reverse any negative affective symptoms 
associated with the nicotine withdrawal syn- 
drome. However, it remains unclear whether 
nicotine has the same effect on negative affect 
that is not associated with nicotine withdrawal. 
In some studies, administration of nicotine exhi- 
bits the expected mood-alleviating properties. 
Specifically, older heavy smokers show dose- 
dependent relief from stress and anxiety 
following nicotine administration (Gilbert, 
Robinson, Chamberlin, & Spielberger, 1989), 
with higher doses of nicotine producing the 
greatest mood relief (Gilbert et al., 1989; 
Perkins et al., 1993). In addition, nicotine 
replacement therapy produces clinically signifi- 
cant reductions in symptoms of depression 
among nonsmokers suffering from major 
depression (Salin-Pascual, Rosas, Jimenez- 
Genchi, & Rivera-Meza, 1996). Nevertheless, 
mood responses that are not shown to be 
related to nicotine withdrawal are highly 
variable. For instance, some evidence actually 
indicates that nicotine creates higher levels of 
anxiety and stress (Parrott, 1999; Piasecki & 
Baker, 2000). Similarly, smoking in response to 
depression may increase, rather than decrease, 
symptoms of depression among smokers with 
a ruminative coping style (Richmond, Spring, 
Sornmerfeld, & McChargue, 2001). 
Despite the apparent inconsistencies shown 
among studies examining negative mood relief 
from nicotine administration, the importance 
of the negative reinforcing properties of nico- 
tine should not be minimized. In fact, if only a 
fraction of individuals achieve negative mood 
relief from the administration of nicotine, nega- 
tive affect's role in the maintenance of tobacco 
use behaviors remains quite salient. For 
example, both baseline and post-quit negative 
affect predict relapse (Pomerleau, Adkins, & 
Pertschuk, 1978; Swan, Ward, & Jack, 1996; 
West et al., 1989). Furthermore, a large portion 
of tobacco users suffer from psychological 
problems that are associated with affective dys- 
regulation (Breslau, 1995). Finally, personality 
traits that increase the likelihood of experienc- 
ing frequent and persistent bouts of negative 
affect predict tobacco use behaviors and relapse 
(Gilbert & Gilbert, 1995). Although it remains 
unclear as to the properties of nicotine that neg- 
atively reinforce tobacco use, there is sufficient 
evidence to implicate the importance of nega- 
tive reinforcement in nicotine dependence. 
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Classical Conditioning: 
A Sto y of Automatic Processes 
Classical conditioning occurs when nico- 
tine administration (unconditioned stimulus) 
produces psychological and physiological 
states (unconditioned response) that are 
repeatedly paired with neutral stimuli (condi- 
tioned stimulus). In other words, chronic nico- 
tine administration elicits many reinforcing 
properties that eventually become conditioned 
to environmental and psychological stimuli 
(Iwamoto, Fudala, Mundy, & Williamson, 
1987; Rose & Levin, 1991). Over time, the 
repeated pairings between the once neutral 
stimuli and nicotine administration produce 
conditioned responses that initiate and main- 
tain tobacco use behavior (Rose & Levin, 
1991). Conditioned responses from emotional 
and environmental cues reflect the activation 
of cognitive (Tiffany, 1990), emotional (Baker 
et al., 1986), and physiological (Robinson & 
Berridge, 2000) domains. Exposure to such 
cues evokes strong tobacco use motivation or 
urges. Some researchers hypothesize that 
this increase in motivation reflects the desire 
to evoke a pleasant feeling or to take away 
unpleasant states (Baker et al., 1986), whereas 
others view this increased motivation as more 
automatic (Tiffany, 1990), that is, driven by 
sensitized neurobiological systems (Robinson 
& Berridge, 2000). 
OTHER IMPORTANT 
FACTORS IN NICOTINE 
DEPENDENCE RESEARCH 
Genetics 
The development of nicotine dependence 
cannot result entirely from random inter- 
actions between neurobiological and psy- 
chosocial factors. It has been suggested that 
individuals who use tobacco and become nico- 
tine dependent may be different from individu- 
als who do not use tobacco because of 
biologically based predispositions that produce 
qualitatively different reinforcement from 
nicotine administration (Pomerleau & Kardia, 
1999). Evidence supporting the notion that 
genetic factors dictate who is likely to become 
nicotine dependent comes from a variety of 
sources. For example, twin studies have shown 
greater concordance rates in monozygotic 
twins than in dizygotic twins, with heritability 
estimates of 53% for tobacco use (see review 
by Hughes, 1986). In addition, certain individ- 
uals may be more sensitive to nicotinic proper- 
ties than are others. A selective sensitivity to 
nicotine is hypothesized to produce more rapid 
tolerance and more extensive self-administra- 
tion patterns (Pomerleau, 1995). As such, 
genetic factors may help to explain why certain 
subgroups of smokers become more dependent 
at earlier ages (e.g., Madden et al., 1999) and 
have extreme difficulties in quitting (e.g., 
Lerman et al., 1999). 
Gender and Ethnicity 
Rates of nicotine dependence appear to dif- 
fer across gender and ethnic groups. In addi- 
tion, the proportions of men and women who 
use tobacco products vary greatly in some 
countries, such as Japan and Greece, but not in 
others, such as the United States and the United 
Kingdom (Grunberg, Winders, & Wewers, 
1991). Thus, it may be that tobacco use is rein- 
forced differently for women in countries where 
as many women use tobacco products as do 
men. In addition, certain minority populations 
(e.g., Afr~can Americans) within the United 
States report higher rates of tobacco use than 
do Caucasians (CDC, 1999), and women and 
minorities appear to be less successful at quit- 
ting (Piper, Fox, Welsch, Fiore, & Baker, 
2001). Therefore, these individuals are at 
greater risk for contracting smoking-related ill- 
nesses, making it very important to consider 
how gender and ethnicity influence the recruit- 
ment, retention, and treatment of nicotine- 
dependent individuals (Piper et al., 2001). 
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More is known about the etiology and 
treatment of nicotine dependence for women 
than for different ethnic groups. The scarcity of 
research on minorities that use tobacco products 
has led many researchers and practitioners to 
examine nicotine dependence among minority 
populations. Contemporary knowledge regard- 
ing what motivates U.S. women to use tobacco 
products, pamcularly cigarettes, has focused on 
two primary issues: (a) affect regulation and 
(b) weight control. In general, women are more 
affectively vulnerable than men, and it is 
believed that ths vulnerability is well suited for 
nicotine's mood-alleviating effects. As such, 
women may receive greater mood regulatory 
benefits from smokmg than do men, and this is 
believed to partially explain why women have 
more difficulty in quitting (Piper et al., 2001). In 
addition, women frequently express concern 
about gaining weight after they quit smoking 
(Klesges & Klesges, 1988). This concern is not 
surprising given that individuals who are absti- 
nent for 1 year will gain an average of 13 
pounds (Klesges et al., 1997). 
Comorbid Personality 
and Psychopathology 
The influence of personality on tobacco use 
is based on the belief that traits predispose 
people to frequent and persistent aversive 
mood states (Cloninger, 1987; Tellegen, 1985; 
Tornkins & McCarter, 1964). As such, many 
theorize that chronic exposure to mood dysregu- 
lation ~rovides ample opportunity for people to 
learn that tobacco products are an efficient 
source of relief from these problematic affective 
states. Traits that are associated with compro- 
mised affective systems and tobacco use behav- 
ior include sensation seeking, neuroticism, 
extroversion, and psychoticism (Gilbert & 
Gilbert, 1995; Spielberger &Jacobs, 1982). 
Contemporary research has identified an 
overwhelming proportion of patients with psy- 
chiatric mood, anxiety, and psychotic prob- 
lems as possessing high levels of comorbid 
nicotine dependence (Hughes, Hatsukami, 
Mitchell, & Dahlgren, 1986). Comorbid psy- 
chopathology represents an important issue 
to address in nicotine dependence research 
because these individuals report excessive 
dependence levels and have extreme difficulty 
in quitting (Hughes et al., 1986; McChargue, 
Gulliver, & Hitsman, 2002a, 2002b). More- 
over, psychiatric smokers are at a heightened 
risk of smoking and psychiatric-related health 
problems as compared with nonsmoking psy- 
chiatric patients and nonpsychiatric smokers 
(Jeste, Gladsjo, Lindamer, & Lacro, 1996; 
Linkins & Cornstock, 1990). Prevalence rates 
of smoking among this population range from 
31% to 90%, depending on the psychiatric 
disorder (Beckham et al., 1997; de Leon et al., 
1995; Hughes eta]., 1986). 
It has been hypothesized that chronic 
tobacco use observed among individuals with 
psychopathological problems reflects self- 
medicating behaviors. According to the self- 
medication hypothesis, psychiatric patients 
smoke in part because nicotine helps to regu- 
late their symptomatology (Gilbert & Gilbert, 
1995). For example, patients with major 
depression may smoke to improve depressed 
mood states (Hall et al., 1993). Similarly, 
patients with schizophrenia may find that 
smoking helps to reduce negative symptoms 
such as anhedonia, apathy, blunted affect, and 
emotional withdrawal (McChargue et al., 
2002a, 2002b). Finally, patients with posttrau- 
matic stress disorder and other anxiety disor- 
ders may smoke to cope with emotional and 
physiological distress (Beckham et al., 1997). 
This self-medication process transforms 
tobacco use into an extremely rewarding 
behavior for psychiatric individuals as com- 
pared with nonpsychiatric cohorts who 
report similar tobacco use patterns (Spring, 
Pingitore, & McChargue, in press). As such, 
the goal of complete abstinence might not 
be initially possible for some psychiatric 
subgroups (e.g., individuals diagnosed with 
schizophrenia). These individuals may require 
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a stepped care approach that focuses on 
reducing exposure to tobacco toxins until the 
individuals are able to stabilize lower rates of 
tobacco use and learn adequate coping skills 
(McChargue et al., 2002a, 2002b). 
ASSESSMENT AND TREATMENT 
As discussed earlier, nicotine dependence is 
maintained by many factors across diverse 
patient populations. Another issue that leads 
to difficulties in the treatment and assessment 
of nicotine dependence is the pervasive nature of 
tobacco use. Specifically, the widespread use of 
tobacco products forces clinical health psychol- 
ogists to address issues related to this construct 
in a variety of settings and situations. Hence, 
clinicians are encouraged to be mindful of the 
settings or situations in which they deliver their 
interventions (Collins et al., 1999). Overall, 
it is recommended that a multidisciplinary 
approach to the assessment and treatment of 
nicotine dependence be used if long-term absti- 
nence is to be achieved (Fagerstrom, 1991). 
Assessment of Nicotine Dependence 
The assessment of nicotine dependence 
may take many forms at differing levels of 
intensity within behavioral medicine settings. 
For example, the approach to assessments of 
nicotine dependence in an emergency room is 
likely to differ from the approach to assess- 
ments used in outpatient settings. Therefore, 
the assessment should be tailored to the spe- 
cific setting. Prior to beginning an assess- 
ment, the clinician should consider the 
purpose for the assessment, the environment 
where the assessment will take place, and the 
form of intervention conducive to the setting. 
Pretreatment Assessments 
To provide adequate treatment, it is 
essential that the clinician conduct the 
most comprehensive evaluation possible. The 
evaluation should include the assessment of 
physiological, psychological, and social factors 
that appear to Influence the patient's tobacco 
use patterns (Ockene, Kristeller, & Donnelly, 
1999). Pertinent information may be acquired 
via a clinical interview, self-report measures, a 
chart review, and corroboration from behav- 
ioral medicine staff. Ockene and colleagues 
(1999) noted that, at the very least, an assess- 
ment of nicotine dependence starts with a 
clinical interview. During this interview, physi- 
ological assessment questions should include 
past quit attempts, withdrawal symptoms expe- 
rienced during past quit attempts, and the 
patient's perceived addiction to nicotine. 
Questions within the social domain should 
include the number of friends, family members, 
and coworkers who use tobacco products; the 
expected amount of social support or nonsup- 
port; and the degree to whch the patient can be 
assertive at rebuffing pressure from others to 
smoke (Ockene et al., 1999) . Included withn 
the psychological assessment should be ques- 
tions related to emotional problems (e.g., stress, 
depression), behavioral indexes (e.g., extent to 
which person will go to have a cigarette), and 
cognitive factors (e.g., self-efficacy beliefs about 
quitting [Ockene et al., 19991). Ockene and 
colleagues (1999) also noted that gathering 
information about a patient's smoking history, 
as well as having the patient self-monitor his or 
her smoking behavior, can provide useful data 
that may aid in treatment specificity. Finally, 
health factors that may be a consequence of 
chronic use patterns should also be assessed, 
and patients who present with physical com- 
plaints (e.g., shortness of breath) should be 
referred to a physician (Ockene et al., 1999). 
Pretreatment assessment can be as brief as a 
10-minute clinical interview or as long as a 2%- 
hour structured assessment. Again, the setting 
and purpose of the assessment should dictate 
the type of assessment administered. For a rela- 
tively brief assessment or for information that 
will be incorporated within a larger assessment, 
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there are a variety of standardized self-report 
measures that can be used to assess level of 
dependence, self-efficacy, readiness to quit, gen- 
eral reasons for use, and perceptions of what 
tobacco products do for the person. For more 
comprehensive interviews, several structured 
and semistructured interviews are available, 
including the Diagnostic Interview Schedule 
(Malgady, Rogler, & Tryon, 1992) and the 
Structured Clinical Interview for the DSM-IV 
Axis I Disorders-Clinician Version (First, 
Spitzer, Gibbon, & Williams, 1997). 
Most self-report measures have adequate psy- 
chometric properties and have been used with a 
variety of populations. Although a detailed 
description of all tobacco-related measures avail- 
able is beyond the scope of t h s  chapter, the 
following measures are recommended. 
1. The Fagerstrom Test of Nicotine 
Dependence (Heatherton, Kozlowski, 
Frecker, & Fagerstrom, 1991): This is a 6- 
item, self-report questionnaire designed to 
assess various components of smoking 
behavior, including an estimate of daily 
intake, difficulty in refraining, and other 
aspects related to the pattern of intake. 
2. The Smoking Self-Efficacy Questionnaive 
(Colletti, Supnick, & Payne, 1985): This is 
a 17-item questionnaire designed to assess 
respondents' beliefs about their ability to 
control their urges to smoke in a variety of 
situations. 
3. The Smoking Consequences Questionnaire 
(Brandon & Baker, 1991): The Smoking 
Consequences Questionnaire (SCQ) is a 50- 
item measure designed to assess expectations 
associated with cigarette smoking. It has four 
factors: negative consequences (e.g., health 
risks), positive reinforcemendsensory satis- 
faction (e.g., taste, relaxation), negative rein- 
forcemendnegative affect reduction (e.g., 
reduction of sadness and anxiety), and 
appetitelweight control. The SCQ-Adult 
(Copeland, Brandon, & Quinn, 1995) is an 
extension of the SCQ for use with an older 
population of dependent smokers. 
4. The Contemplation Ladder (Biener & 
Abrams, 1991): This is a measure of readi- 
ness to consider tobacco cessation. It is 
designed to assess a tobacco user's position 
on a continuum ranging from having no 
thoughts of quitting to being engaged in 
action to change one's tobacco use. The 
ladder is consistent with Prochaska and 
DiClemente's (1983) model, which states 
that tobacco cessation is the culmination of 
an extended process of behavior change. The 
measure employs a picture of a ladder, where 
each rung has an associated number that the 
patient is instructed to circle representing 
where he or she is in thinking about quitting. 
Posttreatment Assessments 
Posttreatment assessment allows the clini- 
cian to measure and adjust treatment efforts as 
necessary. Issues that may arise include treat- 
ment compliance, sudden exacerbation of 
clinical disorders (e.g., major depression), 
severe tobacco withdrawal, intense and persis- 
tent urges to use nicotine, weight gain, brief 
smoking lapses, and abstinence status. Many of 
these issues can be assessed using clinical inter- 
views. A supplementary self-report measure is 
the Minnesota Nicotine Withdrawal Scale 
(Hughes & Hatsukami, 1986), which assesses 
withdrawal severity. This measure may be used 
repeatedly to assess withdrawal across time. 
For purposes of assessing treatment compli- 
ance, lapsing, and abstinence status, the clini- 
cian may assess tobacco use daily, weekly, or at 
designated follow-up times. Self-reported lapses 
and relapses in isolation or combined with bio- 
chemical verification have been used. A detailed 
description of the utility of biochemical mark- 
ers of tobacco and cessation as well as recom- 
mendations for their application in clinical 
practice is beyond the scope of this chapter. 
However, the Society for Research on Nicotine 
and Tobacco Subcommittee on Biochemical 
Verification (2002) recently published an 
overview of this subject. In general, the com- 
mittee noted that there are currently three 
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biomarkers used to assess whether a person has 
been abstinent from nicotine: thiocyanate 
(SCN), cotinine, and expired carbon monoxide 
(CO). SCN and cotinine are metabolites of 
nicotine that indicate tobacco use over the 
past week, and CO (as obtained via expired air) 
indicates smoked tobacco use within the past 
24 hours. The committee also noted that 
the standard indication of tobacco use has 
been cotinine levels above 15 nanograms per 
milliliter, carbon monoxide levels above 8 to 10 
parts per million, and SCN levels of 78 to 84 
micromoles per liter. (For a more in-depth 
review of biochemical verification recommen- 
dations, see Society for Research on Nicotine 
and Tobacco Subcommittee on Biochemical 
Verification, 2002.) 
Treatment of Nicotine Dependence 
The treatment of nicotine dependence 
should be viewed as a multidisciplinary 
stepped care approach. The stepped care 
approach starts with the assessment of the 
patient's motivation to quit and progresses to 
the implementation of brief interventions. For 
example, routine screening and brief counsel- 
ing (less than 3 minutes) within emergency 
rooms increase long-term abstinence rates 
from 3 % (usual care) to 8 % to 11 % (Bernstein 
& Becker, 2002). If the patient is unmotivated 
to quit, the clinician should incorporate 
motivational enhancing techniques within the 
brief intervention. Only after brief inter- 
ventions are unsuccessful should the clinician 
refer the patient to more intensive treatments. 
As discussed in the next two subsections, all 
recommendations for brief and intensive inter- 
ventions are consistent with the clinical prac- 
tice guidelines for treating nicotine dependence 
(Fiore et al., 2000). It should be noted that 
both brief and intensive interventions recom- 
mend the inclusion of pharmacological treat- 
ment. However, pharmacological agents 
associated with treating nicotine dependence 
are discussed in a separate subsection. 
Brief Interventions 
Brief interventions are designed to be used 
in a variety of settings and should not take 
more than 3 to 10 minutes. Brief interventions 
include assessing tobacco use patterns and will- 
ingness to quit, advising the patient to make a 
quit attempt, assisting the patient in quitting, 
and scheduling follow-up sessions (Fiore et al., 
2000). Unfortunately, not all tobacco-using 
patients are highly motivated to quit. In cases 
where the patient is not so motivated, it is rec- 
ommended that the clinician use an empathetic 
therapeutic style that avoids arguments, 
increases self-efficacy, and encourages adaptive 
skills at quitting (Prochaska & Goldstein, 
1991). Confrontational and punitive styles may 
have the opposite effect by further decreasing 
the patient's motivation to quit (Mller & 
Rollnick, 2002). 
Brief assistance that has been shown to 
increase abstinence rates may be as simple as 
providing the patient with self-help material 
combined with recommending approved phar- 
macological treatment (Killen, Fortmann, 
Newrnan, & Varady, 1990). Other brief tech- 
niques include (a) helping to identify upcoming 
challenges, (b) processing helpful skills from 
prior quit attempts, (c) reducing alcohol con- 
sumption during the first month of abstinence, 
(d) encouraging others who use tobacco within 
the same household to quit as well, (e) provid- 
ing social support within the clinical environ- 
ment, and (f) helping the patient to find another 
supportive environment (Fiore et al., 2000). 
The first follow-up session should be sched- 
uled approximately 1 week after the quit date, 
with the second scheduled 1 to 3 weeks later 
(Fiore et al., 2000). During the follow-up, the 
clinician should remain supportive, highlight 
successes (no matter how small), and encour- 
age problem solving. The patient may have a 
tendency to overemphasize an aspect of the 
quit attempt that is linked to failure (Shiffman 
et al., 1996). If so, the clinician should try to 
reframe the perceived failure as a learning 
11 2 1 BEHAVIORS THAT COMPROMISE HEALTH 
experience and reengage the patient in prob- 
lem solving (Fiore et al., 2000). 
Intensive Treatments 
It is recommended that intensive treat- 
ments be offered to all tobacco users because, 
on average, such interventions are more effec- 
tive than brief interventions (Fiore et al., 
2000). This recommendation, however, 
might not be feasible. Thus, for each individ- 
ual who wishes to quit, the clinician is 
encouraged to use a stepped care approach 
that starts brief and progressively increases in 
intensity. The reason for this is that, under 
certain circumstances, brief interventions can 
be more effective than intensive interventions 
(Smith et al., 2001), and brief interventions 
are more practical in a variety of settings (e.g., 
primary care facilities). 
Treatment Format for Intensive 
Treatments. To qualify as an intensive treat- 
ment, there must be a minimum of four ses- 
sions lasting more than 10 minutes each (Fiore 
et al., 2000). If feasible, group sessions of 8 to 
10 people are recommended over individual 
sessions because the group setting fosters social 
support (Ockene et al., 1999). Sessions should 
be scheduled on a weekly basis during the ini- 
tial 4 weeks of treatment and then biweekly for 
the next 4 weeks (Ockene et al., 1999). Finally, 
posttreatment follow-ups should be scheduled 
6 to 12 months after the quit date (Kozlowski, 
Henningfield, & Brigham, 2001). 
Treatment Components. Many of the psy- 
chosocial components used in tobacco cessation 
treatment packages are cognitive-behavioral in 
nature. The purpose of these components is to 
break the association between smoking and 
other Me activities and to increase the patient's 
ability to cope during abstinence. As stated 
earlier, pharmacological therapies are highly 
recommended in conjunction with these 
psychosocial interventions. 
Before a patient attempts to quit, the patient 
is encouraged to gather as much about his or 
her smoking habit as possible. The patient is 
asked to pay attention to specific triggers that 
he or she believes will challenge the attempt 
at quitting. Tobacco-related triggers include 
situations, emotions, thoughts, and places 
that evoke strong urges to use tobacco. Self- 
monitoring smoking behavior prior to a quit 
attempt often will help the patient to identify 
tobacco-related triggers that are relevant to his 
or her life. However, it is not atypical for many 
other "unexpected7' triggers to arise once the 
patient has achieved abstinence. Thus, it is 
important to continue monitoring triggers long 
after the quit date. It is also suggested that the 
clinician provide the patient with education 
regarding the withdrawal symptoms that he or 
she may experience as well as the addictive 
nature of tobacco because this information can 
aid the patient in understanding the process of 
addiction (Fiore et al., 2000; Kozlowski et al., 
2001). For example, skills training focused on 
problem solving and symptom management 
are helpful (Fiore et al., 2000). In addition, 
there are several nonspecific treatment factors 
that the clinician should provide during treat- 
ment. These treatment factors include dis- 
cussing and eliciting positive expectancies, 
being supportive and understanding, and pro- 
viding a time line for the quit attempt (Fiore 
et al., 2000; Kozlowski et al., 2001). 
Once the patient quits, he or she may expe- 
rience a variety of nicotine withdrawal symp- 
toms that undermine quit attempts. It is 
important for the clinician to assist the patient 
in coping with these symptoms, particularly 
during the first month of abstinence. The clin- 
ician should encourage the patient to use the 
skills he or she learned during the pre-quit ses- 
sions. For example, encouraging the use of 
relaxation techniques (e.g., removing oneself 
from stressful situations, deep breathing) 
provides an alternative means by which to 
cope with stressful situations and negative 
affect associated with tobacco withdrawal 
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(Dziegielewski & Eater, 2000; Hatsukami & 
Lando, 1999). The use of accessible substi- 
tutes, such as chewing gum, may also help the 
patient to cope with withdrawal symptoms 
(Cohen, Britt, Collins, al'Absi, & McChargue, 
2001; Cohen, Britt, Collins, Stott, & Carter, 
1999; Cohen, Collins, & Britt, 1997). In addi- 
tion, encouraging the patient to avoid situa- 
tions where tobacco use is likely to occur (e.g., 
bars, bowling alleys) as well as to engage in 
healthy alternative behaviors (e.g., exercise) 
may help to prolong abstinence (Dziegielewski 
& Eater, 2000; Ockene et al., 1999). 
Finally, working with the patient to develop 
the requisite skills to elicit social support from 
others outside of treatment is integral to suc- 
cessful tobacco cessation (Fiore et al., 2000). 
One type of social support outside of therapy 
that should be suggested is Nicotine Anony- 
mous (NicA). These mutual-help groups pro- 
vide social and emotional support for many 
sufferers of addictive disorders through per- 
sonal sharing on a weekly basis (Lichtenstein, 
1999). It has been suggested that NicA may be 
most effective for highly dependent smokers or 
those who also abuse another substance (e.g., 
alcohol). At the very least, patients who do not 
have a significant outside support system may 
need more frequent contact from a clinician 
to support them during their quit attempts 
(Ockene et al., 1999). 
Pharmacological Interventions 
According to the Clinical Practice Guidelines 
(Fiore et al., 2000), many first-line medications 
exist for the treatment of nicotine dependence, 
as do several second-he medications. First-he 
medications have been established as efficacious 
through clinical trials and have been approved 
by the Food and Drug A h s t r a t i o n  (FDA) 
for use with nicotine dependence. First-line 
medications include nicotine replacement prod- 
ucts (e.g., gums, patches, nasal sprays, mhalers) 
and buproprion-SR (sustained release). With the 
exception of nicotine gurn, these interventions 
have been shown to approximately double 
abstinence rates when compared with placebo 
treatments. 
Second-line treatments have also been 
found to be efficacious, but the use of these 
medications is limited due to the lack of FDA 
approval as treatment for nicotine depen- 
dence as well as concerns about potential 
side effects. Second-line treatments include 
fluoxetine, clonidine, nortriptyline, and a 
combination of nicotine replacement thera- 
pies. Mention of second-line therapies is lim- 
ited to this paragraph because such therapies 
are not viable treatment options at this time. 
Thus, this subsection limits further discus- 
sion of pharmacology to first-line treatments. 
Nicotine Replacement Therapy. Nicotine 
replacement therapy (NRT) is intended to 
break the conditioning of nicotine with envi- 
ronmental cues by making nicotine intake 
independent of events in the environment 
(Glover & Glover, 2001). Although NRT 
provides lower doses of nicotine than do 
other tobacco products, it can be used to 
decrease the severity of withdrawal symp- 
toms by providing a slow consistent dose of 
nicotine through an alternate administration 
route (Jarvis & Sutherland, 1998). NRT 
comes in many different forms, including 
gums, patches, nasal sprays, and inhalers. 
Nicotine Polacrilex (gurn) was the first 
NRT approved by the FDA (Jarvis & 
Sutherland, 1998). The absorption rate is fairly 
rapid, and peak nicotine levels are reached 
within 20 to 30 minutes (Hatsukami & 
Lando, 1999). Use is recommended for 3 
months (Hatsukami & Lando, 1999). Although 
nicotine gurn can be used on an as-needed basis 
to control tobacco urges, a fixed schedule has 
been shown to be more effective in dealing 
with withdrawal symptoms (Ockene et al., 
1999). Nicotine gum is dispensed in 2- or 
4-milligram doses, with the 4-milligram dose 
recommended for heavily dependent smokers 
(Fiore et al., 2000). 
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The nicotine patch has a passive delivery 
system. The absorption of nicotine is slower 
than with the gum (Jarvis & Sutherland, 1998), 
resulting in peak levels of nicotine 4 to 9 hours 
after administration (Hatsumaki & Lando, 
1999). The patch is available in either 24-hour 
(Habitrol, Nicoderm, and Nicoderm CQ) or 
16-hour doses (Nicotrol). Typically, 24-hour 
patches have 21 or 22 milligrams of nicotine, 
whereas patches designed for 16-hour use have 
15 milligrams of nicotine (Hatsukami & 
Lando, 1999; Ockene et al., 1999). 
A nicotine nasal spray is available with a 
prescription (Fiore et al., 2000) and 
decreases craving within minutes of use due 
to rapid absorption rates (Hatsukami & 
Lando, 1999; Jarvis & Sutherland, 1998; 
Ockene et al., 1999). Treatment is typically 6 
to 8 weeks but can be extended to 3 months 
in severe cases (Hatsukami & Lando, 1999; 
Ockene et al., 1999). It is important to note 
that the nasal spray may be more effective in 
situations where instant relief from nicotine 
craving is a priority (Hurt et al., 1998). 
Finally, the nicotine inhaler dispenses 10 d- 
ligrarns of nicotine per Inhaler cartridge (Eissen- 
berg, Stiker, & Henningfield, 1999; Hatsukami 
& Lando, 1999). A unique feature of the inhaler 
is that it provides oral and t a d e  reinforcement 
because it consists of a mouthpiece and a nicotine 
cartridge as well as nicotine (Hatsukami & 
Lando, 1999; Ockene et al., 1999). 
Non-nicotine Therapies. Buproprion is 
an antidepressant medication that has been 
shown to aid in the management of nicotine 
withdrawal symptoms (Johnston, Robinson, 
Adams, Glassman, & Covey, 1999). Although 
the mechanism of buproprion is not com- 
pletely clear (Johnston et al., 1999), it is pre- 
sumed to block neural reuptake of dopamine 
and/or norepinephrine (Fiore et al., 2000). 
Buproprion remains the only non-nicotine 
medication used in tobacco cessation pro- 
grams that is approved by the FDA (Fiore 
et al., 2000; Johnston et al., 1999). 
I f  All Else Fails. . . 
If all else fails, the clinician is advised to lower 
tobacco use behavior when abstinence appears 
to be initially unattainable (McChargue et al., 
2002a, 2002b) and/or pharmacological thera- 
pies are not suitable (Ockene et al., 1999). 
Reducing tobacco use may be accomplished via 
nicotine fading. Nicotine fading involves switch- 
ing to a brand with lower nicotine levels as well 
as gradually decreasing the quantity of tobacco 
used (Ockene et al., 1999). For example, once 
cigarette consumption has been decreased to 5 
to 10 cigarettes per day and has been stabilized 
at this level, a quit date should be reestablished 
(Ockene et al., 1999). 
CONCLUSIONS 
Chronic use of tobacco products has been 
linked to a number of serious health problems 
that affect many people throughout the 
world. It appears that nicotine dependence 
develops via the interaction between neurobi- 
ological substrates and cognitive, behavioral, 
and emotional domains. Although there are a 
variety of factors that contribute to the devel- 
opment of nicotine dependence, once people 
are dependent, it is clear that they have 
extreme difficulty in quitting. For the most 
part, treatment of nicotine dependence takes 
a stepped care approach, which begins with 
brief interventions and progresses to more 
intensive interventions. The goal of this chap- 
ter was to increase knowledge about nicotine 
dependence and to provide guidance on inter- 
vention strategies for treating individuals with 
nicotine dependence. Given the pervasiveness 
of tobacco use disorders among various 
patient populations and the health conse- 
quences associated with these disorders, treat- 
ment of nicotine dependence is one area in 
which clinical health psychologists can have a 
positive impact on their patients' overall 
health status. 
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CASE STUDY 
This case study illustrates an intensive smoking treatment. The client, "Betty," was 
a 67-year-old Caucasian female who was referred by her primary care physician 
for individual smoking treatment. Betty presented with complaints of having "no 
control" over her smoking behavior but having a strong desire to quit smoking. 
She also reported that her health was "failing" and that her physician would not 
perform "a necessary medical procedure" unless she quit. Specifically, Betty noted 
that she suffered from numerous medical problems, including chronic bronchitis, 
asthma, and emphysema. Medical concerns had reduced her independence by 
causing her to rely on a motorized scooter for community mobility. Betty reported 
that she lived in an apartment by herself and noted that she had very little local 
social support. She did indicate, however, that she had several relatives who lived 
"out of state" with whom she talked via phone on a weekly basis. 
During Betty's intake session, she was asked to exhale into a CO monitor and to 
complete the Fagerstrom Test of Nicotine Dependence. Results revealed a CO read- 
ing of 48 parts per million (indicating heavy smoking rates) and a test score of 9 (indi- 
cating a high level of nicotine dependence). In addition to these measures, a detailed 
account of her smoking history and quit attempts was obtained via clinical interview. 
In sum, Betty reported smoking her first cigarette at the age of 12 years and pro- 
gressing to daily cigarette smoking by the age of 14 years. She noted that when she 
was smoking at her heaviest rate, she smoked two packs (40 cigarettes) per day, but 
she was currently smoking 25 cigarettes per day. Betty reported that she had tried 
unsuccessfully to quit smoking many times in her life, noting that she could recall four 
occasions when she made "serious attempts" to quit by using group smoking cessa- 
tion programs, using nicotine replacement patches, and stopping "cold turkey." Betty 
made it clear to the therapist that she did not want to use nicotine replacement 
patches this time because she had "vivid disturbing dreams" the last time she had 
used them. She noted that her previous quit attempts resulted in temporary cessation, 
with her longest period of abstinence being a little more than 1% years. She also 
noted, on a scale of 1 to 10, that she had a strong desire to quit smoking (10110), that 
it was very important that she quit smoking (10110), but that she was only somewhat 
confident in her ability to quit (5110). 
Betty agreed to attend weekly sessions for the next 8 weeks. Betty and the 
therapist collaboratively planned to reduce her nicotine intake and to have her 
learn more about her smoking behavior (e.g., when she smoked, where she 
smoked, why she smoked) during the first 4 weeks of treatment. A quit date was 
set for Week 5, and during Weeks 6 to 8 it was decided that the focus of treatment 
would be on issues related to relapse prevention. Betty left the intake session with 
two "homework" assignments, namely (a) to attempt to reduce smoking intake by 
10% during the week and (b) to keep a written record of her smoking behavior. 
Specifically, each time she was about to smoke a cigarette, Betty was asked to write 
down the time of day, any emotions she was feeling at the time, and the situational 
circumstances that occurred just prior to her smoking. 
- 
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Betty presented for her second session on time and indicated that she 
had reduced her smoking intake successfully and kept accurate records of her 
smoking behavior. She was eager to report that by the end of the week, she was 
able to reduce her smoking to 10 cigarettes per day (a far greater reduction than 
the agreed-on 10%). She also noted that she wanted to smoke more frequently 
than she actually did; however, she "got sick" of writing down all of the requested 
information before each cigarette. She noted that tracking her smoking behavior 
allowed her to cut out many cigarettes that she did not "really need." She also 
indicated that in reducing her smoking intake, she learned that the "cravings" she 
had to smoke throughout the day would not "last forever" and in fact passed 
rather quickly, usually within 10 to 15 minutes. After praising Betty on the 
progress she had made during the past week, the therapist reviewed the "smoking 
record sheets'' that Betty had completed in an attempt to identify commonalities in 
her smoking behavior. Examination of the smoking record sheets revealed that 
Betty smoked most often after eating meals and during times of perceived stress. 
In an attempt to aid Betty during these difficult times, urge control strategies 
were discussed. 
One of the keys to success in smoking cessation is learning how to get through 
urges or cravings to smoke. Given that Betty had already learned how to get 
through some of her urges to smoke, the therapist enlisted Betty's help to get a 
sense of what worked for her during the past week. Betty noted that if she just 
waited long enough, her urge to smoke would go away (although she was quick to 
point out that the urges would return). Building on Betty's success, the therapist 
noted that delaying smoking might not work in all situations and taught Betty a 
number of other urge control strategies that might prove to be useful in situations 
where delaying smoking was too difficult. The therapist outlined five basic 
strategies that Betty could pull from her "tool box" when faced with difficult urges: 
(a) delaying smoking, (b) escaping from situations or events that may contribute to 
the urge, (c) avoiding situations where the temptation to smoke may be too great, 
(d) distracting herself by thinking about or doing other things that she enjoys 
doing, and (e) substituting something else for a cigarette such as sugarless gum, 
candy, or sunflower seeds. (All of these strategies can be remembered by the simple 
yet appropriate acronym of DEADS.) The therapist encouraged Betty to continue 
doing what worked for her the previous week and to try some of the other strate- 
gies that were taught when the urge to smoke surfaced. For "homework," Betty 
was again encouraged to reduce her smoking by 10%. The therapist also encour- 
aged Betty to pick a "smoking place" in her home where she usually did not smoke 
and did not engage in other activities such as talking on the phone, socializing, 
eating, watching television, and reading mail. It was suggested that she smoke only 
in this place, with the idea being that she would not associate smoking in this place 
with any other kind of activity. Also, it would mean that she would have to stop 
what she was doing so as to smoke a cigarette. 
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During the third and fourth weeks of treatment, Betty was able to 
reduce her smoking to 4 cigarettes per day using the strategies discussed earlier. 
In anticipation of the Week 5 quit date, most of the fourth session was centered 
on preparing Betty for her quit attempt. She was instructed to have her final 
cigarette no later than before she went to bed on the night before she was to attend 
her fifth session. She was also encouraged to "seek out and destroy" all of the 
cigarettes that remained in her apartment that evening so as to be sure that there 
would not be any cigarettes readily available to her when she woke up the next 
morning. She was also educated about what types of withdrawal symptoms she 
might expect (e.g., depressed mood, irritability, anxiety) so that they would not 
catch her "off guard." In addition, detailed plans were made outlining how 
she would deal with her cravings to smoke so that she had a "plan of attack" if a 
craving surfaced. She was also encouraged to start thinking about how to reward 
herself once she quit. 
During the fifth session, Betty was not as animated as she had been during the 
previous 4 weeks of treatment. She reported that she had not smoked a cigarette 
since before she went to bed the previous evening; however, she noted that she 
"really wanted one." The therapist reinforced Betty for all of her hard work and 
reminded her that her cravings would pass and that the intensity and frequency 
of the cravings would dissipate over time. The remainder of the session was spent 
discussing the health benefits that she could expect over the next several weeks 
(e.g., decrease in coughing and sinus congestion, increase in overall energy level). 
Finally, Betty was informed that she might "slip" and smoke a cigarette during 
the course of the next week. She was told that this is "normal" and that if it hap- 
pens, she should look at it as just a "slip," not a "total relapse." She was encour- 
aged to get back to being "smoke free" after the slip rather than to give herself 
permission to smoke as many cigarettes as she wanted and view her efforts as a 
failure. 
Sessions 6 to 8 began with Betty exhaling into the CO monitor to show her that 
her CO levels were decreasing, thereby increasing the amount of oxygen that was 
circulating throughout her body. Her readings were 11, 8, and 7, respectively. In 
addition, these sessions centered on ways in which Betty could prevent relapse. She 
had done exceptionally well and did not experience a slip during these 3 weeks. 
Betty and the therapist worked on anticipating difficult situations and planned 
ahead as to how she would cope with these situations if and when they arose. Betty 
was particularly concerned about what she would do in stressful situations that 
were bound to arise in the future. It was discussed how she could take a "time out," 
removing herself from the situation, taking deep breaths, andlor thinking of some- 
thing fun she had recently done rather than smoking. At the end of Session 8, Betty 
was commended for her hard work, given information about local support groups 
(in case she desired additional help), and was scheduled for three "booster 
sessions" 1, 3, and 6 months later. 
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At 1-month follow-up, Betty reported that she had one slip during the holidays 
as she was caught off guard by her "emotions." She noted that she recognized what 
she was doing and immediately put out the cigarette and did not allow herself to 
smoke again. She noted that she repeatedly reminded herself of her hard work and 
told herself that she refused to "go back to Square One." She also noted that this 
slip was a "reality check" and reminded her that she should not get overconfident 
about her progress and that she had to continue to work on her addiction to nico- 
tine. Betty admitted that she "would be lying" if she said she did not want a 
cigarette. But she added that the cravings were not occurring as often and that they 
were not as severe when they did occur. Betty was praised by the therapist and was 
encouraged to "keep her guard up." At the 3- and 6-month follow-ups, Betty 
reported that she had not slipped again and that her energy levels were up. At the 
6-month follow-up, she reported that it looked as though her physician was 
considering performing the medical procedure she needed. 
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